Vaxart to Host Full Year 2023 Business Update and Financial Results Conference Call on March 14

Rhea-AI Summary

Vaxart, Inc. (NASDAQ: VXRT) announces a business update and financial results for the full year ending December 31, 2023. The senior management team will host a conference call on March 14, 2024, at 4:30 p.m. ET.

Conference call to begin at 4:30 p.m. ET

SOUTH SAN FRANCISCO, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced it will provide a business update and report financial results for the full year ended December 31, 2023 after the market close on Thursday, March 14, 2024. The Vaxart senior management team will host a conference call on the same day, beginning at 4:30 p.m. ET.

The conference call can be accessed using the following information:

Webcast: Click here
Date: Thursday, March 14, 2024 – 4:30 p.m. ET
Domestic: (877) 407-0832
International: (201) 689-8433
Conference ID: 13744368

Investors may submit written questions in advance of the conference call to ir@vaxart.com.

A replay of the webcast will be available on the Company’s website at www.vaxart.com following the conclusion of the event.

About Vaxart
Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart believes that its proprietary pill vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s development programs currently include pill vaccines designed to protect against coronavirus, norovirus, and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart’s first immune-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists.

Contacts

Vaxart Media Relations: Mark Herr Vaxart, Inc. mherr@vaxart.com (203) 517-8957

Investor Relations: Andrew Blazier FINN Partners IR@vaxart.com (646) 871-8486

FAQ

When will Vaxart provide a business update and report financial results for the full year ended December 31, 2023?

Vaxart will provide a business update and report financial results on March 14, 2024, after the market close.

What is the date and time of the conference call hosted by Vaxart's senior management team?

The conference call will be held on March 14, 2024, at 4:30 p.m. ET.

How can investors access the conference call?

Investors can access the conference call via webcast or by calling (877) 407-0832 domestically or (201) 689-8433 internationally.

Where can investors submit written questions in advance of the conference call?

Investors can submit written questions in advance to ir@vaxart.com.

Where can a replay of the webcast be found after the conference call?

A replay of the webcast will be available on Vaxart's website at www.vaxart.com.